Showing 1-3 of 3 results
Jan-Henning Klusmann P.D., M.D.
Funded: 02-01-2018 through 01-30-2021
Funding Type: Robert J. Arceci International Innovation Award
Institution Location: Halle,
Institution: Martin-Luther-Universitat Halle-Wittenberg

Infants with blood cancer particularly suffer from the side effects of chemotherapy and have a poor prognosis. This highlights the need for new and innovative treatment approaches. Dr. Klusmann's research team and others have recently revealed the importance of areas in the genome for the development of blood cancer that were previously considered as “junk”. These areas are extremely large and can serve as a unique therapeutic target. Dr. Klusmann will investigate those areas and evaluate therapeutic option to overcome current obstacles in the treatment of infants with blood cancer.

Franck Bourdeaut M.D.
Funded: 10-01-2017 through 09-30-2020
Funding Type: Robert J. Arceci International Innovation Award
Institution Location: Paris,
Institution: Institut Curie

Rhabdoid tumors are highly aggressive cancers that affect infants. Current treatments mostly fail, or provoke severe long-term side-effects. Among promising innovative treatments, immunotherapy has few side-effects and show spectacular efficacy in some adult cancers. Immunotherapy restores the ability of our immune system to reject cancer cells, thanks to their numerous genetic abnormalities. Dr. Bourdeaut's project consists in understanding how rhabdoid tumor cells, which harbor no genetic abnormality, may escape this rejection or, in contrary, how they may be recognized by the immune system. Understanding this may have unexpected and broad consequences for the treatment of RT and other poorly mutated cancers.

Sam Behjati Ph.D, BMMCh., B.A.
Funded: 10-01-2016 through 09-30-2019
Funding Type: Robert J. Arceci International Innovation Award
Institution Location: Cambridge,
Institution: Wellcome Trust Sanger Institute

The seeds of many childhood cancers are likely to be laid during human development before a child is born. Therefore, one may view childhood cancer cells as being stuck in development. Dr. Behjati aims to define at what stage tumour cells are stuck and to find ways of stimulating cancer cells to resume development. He envisions that this will provide a way of maturing cancer cells into harmless, non-cancerous cells. The St. Baldrick’s Robert J. Arceci International Innovation Award is given in honor of the late Dr. Robert Arceci. A pioneer in the field, this award reflects Dr. Arceci’s values including creativity, collaboration, and commitment to early- to mid-career scientists.